Marc Feldmann
| Sir Marc Feldmann | |
|---|---|
| Born |
2 December 1944 Lvov, Poland |
| Residence | London, England |
| Citizenship | Australian/British |
| Fields | Immunology |
| Institutions | Kennedy Institute of Rheumatology, University of Oxford |
| Alma mater | |
| Known for | discovery of anti-TNF therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases |
| Notable awards |
|
Sir Marc Feldmann, AC FAA FRS FRCP FRCPath FMedSci (born 2 December 1944), is an Australian immunologist, and a professor at the University of Oxford.
Feldmann was born 2 December 1944 in Lvov, Poland near the Russian border to a Jewish family who managed to get to France immediately postwar. He emigrated from France to Australia at age eight. After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972 with Sir Gustav Nossal.
He moved to London in the 1970s, working first with Professor Avrion Mitchison at the Imperial Cancer Research Fund's Tumour Immunology Unit, then in 1985 moved to the Charing Cross Sunley Research Centre and the Kennedy Institute of Rheumatology which joined with the Faculty of Medicine at Imperial College in 2000 and in August 2011 the Kennedy Institute of Rheumatology transferred to the University of Oxford.
In the 1980s he published a new hypothesis for the mechanism of induction of autoimmune diseases, highlighting the role of cytokines. Cytokines are potent signalling proteins, local hormones, which drive important processes like inflammation, immunity and cell growth. This model was validated in experiments with thyroid disease tissue. From 1984 he collaborated with Ravinder N. Maini at the Kennedy Institute of Rheumatology to study disease mechanism in rheumatoid arthritis, a much more clinically important autoimmune disease, affecting 1% of the population.
...
Wikipedia